查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1985507

心臟就地檢驗市場：全球市場預測（按產品類型、檢測模式、技術、應用、最終用戶和分銷管道分類）- 2026-2032年

Cardiac Point of Care Testing Market by Product Type, Test Mode, Technology, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，心臟即時檢測市場價值將達到 105.6 億美元，到 2026 年將成長至 118.8 億美元，到 2032 年將達到 259.5 億美元，複合年成長率為 13.70%。

主要市場統計數據
基準年 2025 105.6億美元
預計年份：2026年 118.8億美元
預測年份 2032 259.5億美元
複合年成長率 (%) 13.70%

一個戰略框架，用於理解為什麼加速診斷反應和分散式心臟檢測正在重塑臨床路徑和市場優先事項。

心臟就地檢驗正成為急性和慢性心血管疾病診療路徑中的關鍵轉捩點，它能夠幫助醫生在患者身邊快速做出臨床決策，並將診斷範圍擴展到傳統檢查室之外。近期技術進步縮短了檢測時間，並提高了分析靈敏度。同時，醫療保健的發展趨勢推動了對在急診診所、門診中心、居家醫療機構和醫院檢查室等場所進行分散式檢查的需求不斷成長。這些趨勢正在改變臨床醫生對胸痛進行分診、監測心臟衰竭以及評估心血管風險的方式，更快的診斷結果將帶來更及時的干涉措施和更有效率的診療路徑。

生物標記靈敏度的提高、設備的微型化以及醫療保健服務體系的改革如何重新定義心臟診斷和臨床工作流程。

床邊心臟檢測領域正經歷一場變革，其驅動力來自於技術創新、臨床實踐的進步以及醫療服務體系的改革。高靈敏度生物標記檢測延長了心肌損傷和心臟衰竭的診斷窗口期，因此需要重新評估分診通訊協定，並縮短急診和門診的治療時間。同時，生物感測器的微型化和診斷化學的進步使得在中心檢查室之外也能獲得可靠的定量結果，從而加速了向分散式、以患者為中心的診斷模式的廣泛轉變。

本檢驗了2025 年關稅變化對營運和商業的影響，以及這些變化如何影響供應鏈的韌性、採購變化和定價策略。

2025年實施的累積關稅措施為心臟就地檢驗生態系統帶來了新的商業性和營運複雜性。進口零件、試劑原料和成品診斷設備關稅帶來的成本壓力，促使製造商和經銷商重新思考籌資策略和供應鏈結構。一些企業正在加快供應商多元化的步伐，例如優先選擇關稅較低地區的合作夥伴或尋求近岸外包方案，以降低貿易政策波動帶來的風險。這些策略性因應措施不僅會對採購產生直接影響，還可能影響整個通路的產品定價和利潤率。

透過對產品類型、最終用戶需求、通路、測試模式、技術和臨床應用進行詳細的細分分析，揭示了有針對性的策略重點。

詳細的細分分析揭示了臨床需求、技術適用性和分銷動態之間的交集，從而在整個心臟就地檢驗領域創造了差異化的機會。產品類型細分包括腦鈉肽（BNP）、C反應蛋白、肌酸激酶MB（CK MB）、肌紅蛋白和肌鈣蛋白，其中BNP進一步細分為BNP和N端腦鈉肽前體（Nt-proBNP），C反應蛋白細分為高靈敏度檢測和標準檢測，肌鈣蛋白細分為肌鈣蛋白I和肌鈣蛋白T。終端使用者細分突顯了門診中心、急診診所、居家醫療服務和醫院檢查室的不同部署模式，每種模式都展現出獨特的工作流程要求、人員能力和購買行為。分銷管道包括醫院藥房、線上管道（包括B2B入口網站和D2C（直接面對消費者）服務）以及零售藥房。每個管道都有不同的利潤率預期和客戶參與模式。

醫療保健基礎設施、監管要求和製造生態系統方面的區域差異如何影響部署路徑和策略市場進入方式？

區域趨勢對心臟就地檢驗的推廣路徑、監管預期和供應鏈決策有顯著影響。在美洲，臨床應用主要受急診對快速分診的需求以及居家照護環境中對攜帶式診斷設備日益成長的需求所驅動，而公立和私立醫療系統的採購週期和報銷機制則存在顯著差異。歐洲、中東和非洲（EMEA）的情況則較為複雜，監管協調與市場分散並存，導致每種醫療器材和檢測檢測套組的推廣路徑各不相同。雖然集中式系統在某些地區仍然佔據主導地位，但在其他地區，分散式檢查正迅速普及，這主要得益於公共衛生優先事項和投資能力的推動。亞太地區兼具先進的都市區醫療設備系統（擁有完善的檢測網路）和新興經濟體快速發展的基層醫療基礎設施。此外，該地區的製造能力和供應商生態系統在全球供應鏈中扮演核心角色，影響採購決策和定價趨勢。

競爭與夥伴關係的動態凸顯了成熟和創新平台公司如何利用分銷、連接和證據生成來確保永續的市場地位。

就地檢驗的競爭動態由兩類企業共同塑造：一類是成熟的診斷設備製造商，另一類是專注於特定領域的創新型企業，例如超靈敏生物標記、以用戶為中心的設備設計以及整合式數位生態系統。大型平台公司通常利用其廣泛的分銷網路、完善的監管合規體係以及跨產品組合的協同效應來擴大產品部署，而新興參與企業則專注於其平台的柔軟性、低成本製造或能夠實現快速迭代的新型生物感測器技術。

為製造商、經銷商和醫療保健系統提供可操作且優先的行動方案，以加快部署速度、增強韌性，並使提供的服務與臨床優先事項保持一致。

致力於加速技術普及並建立穩健業務營運的產業領導者應優先考慮一系列切實可行的策略，以平衡臨床可靠性、供應鏈靈活性和終端用戶體驗。首先，投資於能夠將就地檢驗與患者治療路徑中可衡量的改善聯繫起來的臨床證據，例如縮短決策時間、避免不必要的住院治療，並確保這些證據能夠涵蓋各種終端用戶場景，包括門診中心、急診診所、居家醫療和醫院檢查室。其次，透過組裝替代採購管道、盡可能將組裝環節外包以及談判包含價格保護條款的長期供應契約，實現供應鏈多元化並降低關稅和貿易政策帶來的風險。

透過調查方法，結合對臨床醫生的訪談、技術性能評估、監管審查和分銷經濟學，建構了一套嚴謹、多方面的分析。

本研究的綜合分析是基於一種跨學科調查方法，旨在整合臨床、技術、監管和商業性觀點。主要資料來源包括對急診醫學和循環系統臨床醫生、門診和住院採購負責人以及診斷設備製造商和分銷合作夥伴的高管進行的結構化訪談，從而獲得關於推廣應用障礙和工作流程優先事項的定性見解。次要資訊來源包括對同行評審科學文獻、監管指導文件以及近期發表的詳細介紹設備核准、檢測驗證和互通性要求的出版物的系統性回顧。此外，還進行了技術評估，將生物感測器、免疫檢測和橫向流動化驗等分析方法與臨床性能標準和可用性指標進行比較。

簡要概述相關人員應協調一致的臨床、技術和操作要求，以最大限度地發揮分散式心臟診斷的潛力。

總之，心臟就地檢驗在現代心血管診療流程中發揮著至關重要的作用，並有望加快急診、門診和家庭環境中的臨床決策。高靈敏度檢測、生物感測器創新和數位化整合技術的進步正在拓展其應用場景，而不斷變化的報銷機制和法規環境也在影響其普及應用。然而，近期貿易政策的變化凸顯了供應鏈韌性、成本透明度和適應性籌資策略對於維持競爭力以及確保診斷材料穩定供應的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：心臟就地檢驗市場：依產品類型分類

  • BNP
    • BNP
    • NT-proBNP
  • C反應蛋白
    • 高敏C反應蛋白
    • 標準C反應蛋白
  • CK MB
  • 肌紅蛋白
  • 肌鈣蛋白
    • 肌鈣蛋白 I
    • 肌鈣蛋白T

第9章 依檢測模式就地檢驗市場

  • 定性
  • 定量

第10章：心臟就地檢驗市場：依技術分類

  • 生物感測器
    • 電化學感測器
    • 光學感測器
  • 免疫檢測
    • 化學冷光免疫檢測
    • 酵素免疫分析法
  • 橫向流動化驗

第11章 心臟就地檢驗市場：依應用領域分類

  • 心肌梗塞的診斷
  • 心臟衰竭監測
  • 風險評估

第12章 心臟就地檢驗市場：依最終用戶分類

  • 門診部
  • 急診診所
  • 家庭醫療保健
  • 醫院檢查室

第13章：心臟就地檢驗市場：依通路分類

  • 醫院藥房
  • 線上管道
    • B2B入口網站
    • 消費者
  • 零售藥房

第14章 心臟就地檢驗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：心臟就地檢驗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 心臟就地檢驗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國心臟就地檢驗市場

第18章：中國心臟就地檢驗市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abaxis, Inc. by Zoetis Inc
  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • Beckman Coulter
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Cardiac Insight Inc.
  • CardioGenics Holdings Inc.
  • Chembio Diagnostic Systems, Inc. by Biosynex
  • EKF Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • Fujirebio
  • Horiba, Ltd.
  • I-Sens Inc.
  • LifeSign LLC
  • Nexus Dx, Inc. by Sinocare
  • Nova Biomedical
  • PTS Diagnostics by Danaher Corporation
  • Quidel Corporation
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trividia Health, Inc.
Product Code: MRR-3F5063247F53

The Cardiac Point of Care Testing Market was valued at USD 10.56 billion in 2025 and is projected to grow to USD 11.88 billion in 2026, with a CAGR of 13.70%, reaching USD 25.95 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.56 billion
Estimated Year [2026] USD 11.88 billion
Forecast Year [2032] USD 25.95 billion
CAGR (%) 13.70%

A strategic framing of why accelerated diagnostic responsiveness and decentralized cardiac testing are reshaping clinical pathways and market priorities

Cardiac point-of-care testing has emerged as a critical inflection point for acute and chronic cardiovascular care pathways, enabling faster clinical decision-making at the patient's side and expanding diagnostic reach beyond traditional laboratory settings. Recent technological advances have reduced assay run-times and improved analytical sensitivity, while healthcare delivery trends have driven demand for decentralized testing in emergency clinics, ambulatory care centers, home healthcare settings, and hospital laboratories. These dynamics are reshaping how clinicians triage chest pain, monitor heart failure, and stratify cardiovascular risk, with faster diagnostic results translating into more timely interventions and streamlined care pathways.

Concurrently, improvements in immunoassay platforms, lateral flow devices, and biosensor technologies are converging with digital integration and connectivity solutions, enabling more actionable data flows and remote monitoring capabilities. This shift is accompanied by evolving reimbursement and regulatory frameworks that are increasingly accommodating point-of-care modalities, albeit with variability across regions. Therefore, stakeholders-ranging from device manufacturers and distributors to hospital procurement teams and policy makers-must weigh clinical utility, workflow integration, and cost structures when evaluating adoption strategies.

This introduction frames the subsequent analysis by emphasizing clinical impact, technological progress, and operational considerations that together define strategic opportunities and risks in cardiac point-of-care testing.

How advances in biomarker sensitivity, device miniaturization, and care delivery reforms are jointly redefining cardiac diagnostics and clinical workflows

The landscape of cardiac point-of-care testing is undergoing transformative shifts driven by a combination of technological innovation, clinical practice evolution, and healthcare delivery reform. High-sensitivity biomarker assays have extended the diagnostic window for myocardial injury and heart failure, prompting emergency and ambulatory settings to re-evaluate triage protocols and reduce time-to-treatment. At the same time, biosensor miniaturization and improvements in assay chemistry have made reliable quantitative results feasible outside central laboratories, supporting a broader shift toward decentralized, patient-centric diagnostics.

These technology-driven advances are intersecting with shifting care models, where hospital-at-home initiatives, urgent care expansions, and remote monitoring programs are increasing demand for portable, rapid testing. Payment models that reward value-based outcomes and shorter hospital stays further incentivize adoption of point-of-care solutions that can demonstrably reduce length of stay and improve therapeutic targeting. In parallel, digital health integration and interoperability standards are creating expectations for secure data exchange and seamless inclusion of point-of-care results into electronic health records and clinical decision support systems.

Finally, competitive dynamics are changing as established diagnostics companies invest in connectivity and user-experience design, while agile medtech entrants focus on platform flexibility and cost-effective manufacturing. Collectively, these shifts are redefining where and how cardiac biomarkers are measured, how results influence care, and which capabilities will determine market leadership in the near term.

Examining the operational and commercial consequences of 2025 tariff changes and how they compel supply chain resilience, sourcing shifts, and pricing strategies

The introduction of cumulative tariff measures in 2025 has created a new layer of commercial and operational complexity for the cardiac point-of-care testing ecosystem. Tariff-driven cost pressures on imported components, reagent raw materials, and finished diagnostic devices have prompted manufacturers and distributors to reassess sourcing strategies and supply chain architectures. Some organizations have accelerated supplier diversification efforts, prioritizing partners in lower-tariff jurisdictions or pursuing nearshoring options to mitigate exposure to trade policy volatility. These strategic responses have immediate procurement implications and may influence product pricing and margin dynamics across distribution channels.

In practice, increased import costs have been met with a range of adaptations, including longer-term supplier contracts with price-protection clauses, localized assembly to avoid duties on finished goods, and redesigns that reduce dependence on tariff-affected materials. For end users, particularly smaller ambulatory centers and retail pharmacy channels, the pass-through of higher unit costs can constrain adoption momentum unless offset by demonstrable clinical and operational value. Payers and health systems are responding by scrutinizing total cost of care impacts, requiring clearer evidence that point-of-care testing shortens workflows or avoids downstream expenses.

Regulatory and customs processing delays associated with tariff implementation have also highlighted the need for robust inventory planning and buffer strategies. Overall, the tariff environment has elevated supply chain resilience and cost transparency as strategic priorities for manufacturers, distributors, and health system purchasers alike.

Detailed segmentation analysis connecting product categories, end-user requirements, distribution routes, test modes, technologies, and clinical applications to unlock targeted strategic priorities

A granular segmentation analysis reveals where clinical demand, technology fit, and distribution dynamics intersect to create differentiated opportunities across the cardiac point-of-care testing landscape. Product type segmentation encompasses BNP, C Reactive Protein, CK MB, Myoglobin, and Troponin, with further granularity for BNP split into BNP and Nt ProBNP, C Reactive Protein divided into High Sensitivity and Standard assays, and Troponin distinguished between Troponin I and Troponin T. End user segmentation highlights distinct adoption patterns across ambulatory care centers, emergency clinics, home healthcare services, and hospital laboratories, each presenting unique workflow requirements, staffing competencies, and purchasing behaviours. Distribution channels reflect hospital pharmacies, online channels-including Business To Business portals and Direct To Consumer offerings-and retail pharmacies, each channel imposing different margin expectations and customer engagement models.

Test mode segmentation bifurcates the market into qualitative and quantitative modalities, a distinction that maps closely to clinical intent and regulatory scrutiny, while technology segmentation identifies biosensor, immunoassay, and lateral flow assay approaches, with biosensors further categorized into electrochemical and optical sensors and immunoassays differentiated into chemiluminescence immunoassay and enzyme linked immunosorbent assay formats. Application-based segmentation captures the primary clinical use cases of diagnosis of myocardial infarction, heart failure monitoring, and risk assessment, which dictate performance thresholds and integration needs.

Understanding these interlocking segments allows stakeholders to prioritize product development and go-to-market strategies that align analytic performance with user setting, distribution economics, and clinical value propositions, ensuring that innovations address the most pressing unmet needs across care settings.

How regional differences in healthcare infrastructure, regulatory expectations, and manufacturing ecosystems shape adoption pathways and strategic market entry approaches

Regional dynamics exert a material influence on adoption pathways, regulatory expectations, and supply chain decisions within cardiac point-of-care testing. In the Americas, clinical adoption is driven by emergency department demand for rapid triage and by expanding home-based care initiatives that favour portable diagnostics, while procurement cycles and reimbursement mechanisms vary widely between public and private systems. Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts coexist with market fragmentation, leading to differentiated pathways for devices and assays; in some areas, centralized systems remain dominant, whereas other markets show rapid uptake of decentralised testing, often influenced by public health priorities and investment capacity. Asia-Pacific displays a mix of advanced urban healthcare systems with sophisticated laboratory networks and rapidly expanding primary care infrastructures in emerging economies; this region's manufacturing capabilities and supplier ecosystems also play a central role in global supply chains, affecting sourcing decisions and price dynamics.

Each region imposes distinct requirements for clinical validation, quality systems, and distribution partnerships. For manufacturers and distributors, tailoring market entry strategies to these regional specifics-balancing regulatory timelines, channel selection, and local partnerships-will drive market traction. For healthcare providers and payers, regional context determines how point-of-care testing is prioritized within broader cardiovascular care initiatives and how value is assessed against competing clinical investments.

Competitive and partnership dynamics highlighting how platform incumbents and innovators leverage distribution, connectivity, and evidence generation to secure durable market positions

Competitive dynamics in cardiac point-of-care testing are shaped by a mix of established diagnostics manufacturers and agile innovators focusing on niche capabilities such as ultra-sensitive biomarkers, user-centric device design, and integrated digital ecosystems. Large-platform companies often leverage broad distribution networks, established regulatory footprints, and cross-portfolio synergies to scale introductions, while emerging entrants concentrate on platform flexibility, lower-cost manufacturing, or novel biosensor technologies that can be rapidly iterated.

Partnerships and strategic alliances are increasingly common as device developers seek to integrate assay expertise with connectivity providers and sample-to-result automation specialists. This collaborative approach accelerates time-to-market for features that matter to clinicians, such as real-time data transmission to electronic health records and decision-support compatibility. In addition, strategic licensing and OEM arrangements enable companies with strong commercial channels to offer complementary assays under co-branded or private-label models, expanding reach without duplicative infrastructure investments.

From a procurement perspective, health systems prioritize vendors that can demonstrate consistent supply, regulatory compliance, and clear pathways for technical support and training. Companies that invest in post-sales support models, local technical presence, and outcome-oriented evidence generation are best positioned to win durable contracts and to support broader clinical adoption across care settings.

Practical and prioritized actions for manufacturers, distributors, and health systems to accelerate adoption, enhance resilience, and align offerings with clinical priorities

Industry leaders seeking to accelerate adoption and build resilient operations should prioritize a set of actionable strategies that balance clinical credibility, supply chain agility, and end-user experience. First, invest in clinical evidence that links point-of-care testing to measurable improvements in patient pathways, such as reduced time-to-decision or avoidance of unnecessary admissions, and ensure that this evidence addresses different end-user contexts including ambulatory centers, emergency clinics, home healthcare, and hospital laboratories. Second, diversify supply chains to mitigate tariff and trade-policy exposure by developing alternate sourcing options, nearshoring assembly where feasible, and negotiating longer-term supply agreements with price protection.

Third, design product portfolios and distribution approaches tailored to channel economics; hospital pharmacies, online channels including B2B portals and direct-to-consumer routes, and retail pharmacies each require distinct pricing, packaging, and service propositions. Fourth, prioritize interoperability and digital integration so that point-of-care results feed seamlessly into clinical workflows and electronic records, thereby increasing clinical utility and adoption. Fifth, adopt a segmented go-to-market strategy that aligns technologies-whether biosensors, immunoassays, or lateral flow formats-with the specific performance requirements of applications such as myocardial infarction diagnosis, heart failure monitoring, and risk assessment.

By combining robust clinical evidence, supply chain resilience, channel-specific commercial design, digital enablement, and targeted segmentation, industry leaders can create defensible positions and accelerate sustainable uptake of cardiac point-of-care testing solutions.

Methodological approach integrating clinician interviews, technical performance assessments, regulatory reviews, and channel economics to build a rigorous multi-perspective analysis

This research synthesis draws on a multidisciplinary methodology designed to integrate clinical, technological, regulatory, and commercial perspectives. Primary inputs included structured interviews with clinicians in emergency medicine and cardiology, procurement professionals across ambulatory and hospital settings, and executives from diagnostic companies and distribution partners, providing qualitative insight into adoption barriers and workflow priorities. Secondary inputs comprised a systematic review of peer-reviewed scientific literature, regulatory guidance documents, and recent public filings that detail device clearances, assay validations, and interoperability requirements. Additionally, technology assessments were conducted to compare analytical approaches such as biosensors, immunoassays, and lateral flow assays against clinical performance criteria and usability metrics.

Analytical frameworks incorporated segmentation mapping to relate product types and technologies to end-user needs and distribution economics, along with scenario analysis to evaluate operational responses to external pressures such as tariff changes. Care was taken to ensure source triangulation, cross-validating claims from interviews with published validation studies and regulatory documentation. Limitations of the methodology include variable transparency in proprietary supplier cost structures and the evolving nature of trade policy and reimbursement pathways, which may influence implementation timelines. Nonetheless, the approach provides a rigorous basis for strategic decision-making by combining clinician perspectives, technical performance evaluation, and commercial channel analysis.

A concise synthesis of clinical, technological, and operational imperatives that stakeholders must align to realize the full potential of decentralized cardiac diagnostics

In conclusion, cardiac point-of-care testing occupies a pivotal role in modern cardiovascular care pathways, offering the potential to accelerate clinical decision-making across emergency, ambulatory, and home-based settings. The convergence of high-sensitivity assays, biosensor innovations, and improved digital integration is expanding the range of viable use cases, while evolving reimbursement and regulatory contexts are shaping adoption trajectories. However, recent trade-policy shifts underline the importance of supply chain resilience, cost transparency, and adaptive sourcing strategies to maintain competitive positioning and ensure consistent access to diagnostic supplies.

For stakeholders, the imperative is clear: align product performance with specific clinical workflows, demonstrate measurable impacts on patient management, and design distribution and support models that reflect the economic realities of each end-user segment. Companies that combine robust clinical evidence, flexible manufacturing and sourcing approaches, and strong post-sales support will be best positioned to convert technical promise into sustained clinical and commercial success. Moving forward, continued collaboration among manufacturers, clinicians, payers, and regulators will be essential to realize the full potential of decentralized cardiac diagnostics while maintaining quality, affordability, and equitable access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Point of Care Testing Market, by Product Type

  • 8.1. BNP
    • 8.1.1. BNP
    • 8.1.2. Nt ProBNP
  • 8.2. C Reactive Protein
    • 8.2.1. High Sensitivity C Reactive Protein
    • 8.2.2. Standard C Reactive Protein
  • 8.3. CK MB
  • 8.4. Myoglobin
  • 8.5. Troponin
    • 8.5.1. Troponin I
    • 8.5.2. Troponin T

9. Cardiac Point of Care Testing Market, by Test Mode

  • 9.1. Qualitative
  • 9.2. Quantitative

10. Cardiac Point of Care Testing Market, by Technology

  • 10.1. Biosensor
    • 10.1.1. Electrochemical Sensor
    • 10.1.2. Optical Sensor
  • 10.2. Immunoassay
    • 10.2.1. Chemiluminescence Immunoassay
    • 10.2.2. Enzyme Linked Immunosorbent Assay
  • 10.3. Lateral Flow Assay

11. Cardiac Point of Care Testing Market, by Application

  • 11.1. Diagnosis Of Myocardial Infarction
  • 11.2. Heart Failure Monitoring
  • 11.3. Risk Assessment

12. Cardiac Point of Care Testing Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Emergency Clinics
  • 12.3. Home Healthcare
  • 12.4. Hospital Laboratories

13. Cardiac Point of Care Testing Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Channels
    • 13.2.1. Business To Business Portals
    • 13.2.2. Direct To Consumer
  • 13.3. Retail Pharmacies

14. Cardiac Point of Care Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cardiac Point of Care Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cardiac Point of Care Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cardiac Point of Care Testing Market

18. China Cardiac Point of Care Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abaxis, Inc. by Zoetis Inc
  • 19.6. Abbott Laboratories
  • 19.7. ACON Laboratories, Inc.
  • 19.8. Beckman Coulter
  • 19.9. Becton, Dickinson and Company
  • 19.10. Bio-Rad Laboratories, Inc.
  • 19.11. bioMerieux SA
  • 19.12. Cardiac Insight Inc.
  • 19.13. CardioGenics Holdings Inc.
  • 19.14. Chembio Diagnostic Systems, Inc. by Biosynex
  • 19.15. EKF Diagnostics
  • 19.16. F. Hoffmann-La Roche Ltd.
  • 19.17. Fujirebio
  • 19.18. Horiba, Ltd.
  • 19.19. I-Sens Inc.
  • 19.20. LifeSign LLC
  • 19.21. Nexus Dx, Inc. by Sinocare
  • 19.22. Nova Biomedical
  • 19.23. PTS Diagnostics by Danaher Corporation
  • 19.24. Quidel Corporation
  • 19.25. Radiometer Medical ApS
  • 19.26. Randox Laboratories Ltd.
  • 19.27. Siemens Healthineers AG
  • 19.28. Thermo Fisher Scientific Inc.
  • 19.29. Trividia Health, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 232. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 233. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 234. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 237. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 238. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 271. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 272. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 273. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 274. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 276. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 277. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 284. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 285. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 286. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 287. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 289. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 290. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES CARDIAC POINT OF CARE TESTING MARKE